Diadema Partners’s Moderna MRNA Stock Holding History

Diadema Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20,000	Closed	-$517K	–	173
2025 Q3	$517K	Buy	+20,000	New	+$558K	0.13%	97

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Diadema Partners's MRNA Position: Q4 2025 in Review

Diadema Partners sold out of Moderna (MRNA) in Q4 2025, closing a stake of 20,000 shares — an estimated $517K sold.

Diadema Partners first reported a position in MRNA in Q3 2025 and held it in 1 quarter. The position peaked at $517K in Q3 2025. 672 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

Diadema Partners reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 20,000 Moderna shares in Q4 2025, an estimated $517K.
Diadema Partners first reported a position in Moderna in Q3 2025 and held it in 1 quarter.
Diadema Partners's Moderna position peaked at $517K in Q3 2025.
672 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.